Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
RegulatoryapprovedZenbexusPositive
AI Analysis
Summary
Bristol Myers Squibb received FDA approval for Zenbexus, a myeloma drug acquired from Celgene, marking the first approval in the CELMoD protein-degrading medicines class and potentially revitalizing a key drug franchise.
Outcome Details
FDA approval of Zenbexus, first CELMoD protein-degrading medicine in the class
Importance:8/10
Sentiment:
0.85
FDA approvalmyelomaCELMoDCelgene acquisitionprotein degradation
Read the original article
Published by BioPharma Dive on August 14, 2026 4:02 PM